细胞减少根治前列腺切除术（cRP）当前正在对低量转移性激素敏感性前列腺癌（mHSPC）患者进行测试。我们旨在回顾文献，并报告最近的前瞻性研究，探讨cRP在mHSPC患者中的肿瘤学和功能结果。根据前瞻性数据，我们发现在选择适当的低量mHSPC患者中，与单纯系统治疗相比，cRP是可行并且提供有利的肿瘤学结果。此外，在mHSPC中，cRP对局部疾病控制具有益处，不良事件的发生率也是可以接受的。 患者摘要：在本研究中，我们回顾了最近进行的前瞻性研究，分析了在mHSPC患者中进行前列腺手术切除的生存和安全性。我们发现，在选择适当的mHSPC患者中，前列腺手术切除是一种可行、安全且可能有效的治疗方法。 版权所有©2023欧洲泌尿系统学会。由Elsevier B.V.出版。保留所有权利。

Cytoreductive radical prostatectomy (cRP) is currently tested in patients with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). We aimed to review the literature and to report recent prospective studies addressing oncologic and functional results of cRP in mHSPC patients. Based on prospective data, we found that cRP is feasible and provides favorable oncologic outcomes when compared with systemic therapy alone in well-selected patients with low-volume mHSPC. Furthermore, cRP has beneficial effects on local disease control in mHSPC with an acceptable rate of adverse events. PATIENT SUMMARY: In the present study, we reviewed recent prospective studies analyzing the survival and safety of prostate surgical excision in patients with mHSPC. We have found that prostate surgical excision is a feasible, safe, and potentially effective therapy in selected patients with mHSPC.Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.